Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
  • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.


    The EU Clinical Trials Register currently displays   39572   clinical trials with a EudraCT protocol, of which   6487   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2017-001772-28
    Sponsor's Protocol Code Number:PAC203
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Ongoing
    Date on which this record was first entered in the EudraCT database:2017-07-21
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2017-001772-28
    A.3Full title of the trial
    An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib in Patients with Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis Previously Treated with Ruxolitinib
    Estudio de fase II abierto, aleatorizado, de búsqueda de la dosis de pacritinib en pacientes con trombocitopenia y mielofibrosis primaria, mielofibrosis posterior a policitemia vera o mielofibrosis posterior a trombocitemia idiopática tratados previamente con ruxolitinib
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A Phase 2 Dose-Finding Study of Pacritinib in Myelofibrosis Patients
    Estudio de fase II de búsqueda de la dosis de pacritinib en pacientes con mielofibrosis
    A.4.1Sponsor's protocol code numberPAC203
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorCTI BioPharma Corp.
    B.1.3.4CountryUnited States
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportCTI BioPharma Corp.
    B.4.2CountryUnited States
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationCTI BioPharma Corp.
    B.5.2Functional name of contact pointRegulatory Affairs-Sarah H. Telzrow
    B.5.3 Address:
    B.5.3.1Street Address3101 Western Avenue, Suite 600
    B.5.3.2Town/ citySeattle
    B.5.3.3Post codeWA 98121
    B.5.3.4CountryUnited States
    B.5.5Fax number+12062846206
    B.5.6E-mailstelzrow@ctibiopharma.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community Yes
    D.2.5.1Orphan drug designation numberEU3-10-767-003, EU3-10-768-003, EU3-10-769-003
    D.3 Description of the IMP
    D.3.1Product namePacritinib
    D.3.4Pharmaceutical form Capsule, hard
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNPacritinib
    D.3.9.1CAS number 937272-79-2
    D.3.9.2Current sponsor codeSB1518
    D.3.9.3Other descriptive namePACRITINIB
    D.3.9.4EV Substance CodeSUB114513
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number100
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Primary Myelofibrosis, Post-essential thrombocythemia myelofibrosis, Post polycythaemia vera myelofibrosis
    Mielofibrosis primaria, mielofibrosis posterior a policitemia vera, mielofibrosis posterior a trombocitemia idiopática
    E.1.1.1Medical condition in easily understood language
    Primary or Secondary Myelofibrosis (MF)
    Mielofibrosis (MF) primaria o secundaris
    E.1.1.2Therapeutic area Diseases [C] - Cancer [C04]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level PT
    E.1.2Classification code 10077161
    E.1.2Term Primary myelofibrosis
    E.1.2System Organ Class 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level LLT
    E.1.2Classification code 10074692
    E.1.2Term Post essential thrombocythaemia myelofibrosis
    E.1.2System Organ Class 100000012930
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level LLT
    E.1.2Classification code 10074691
    E.1.2Term Post polycythaemia vera myelofibrosis
    E.1.2System Organ Class 100000012930
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level PT
    E.1.2Classification code 10028537
    E.1.2Term Myelofibrosis
    E.1.2System Organ Class 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    E.1.3Condition being studied is a rare disease Yes
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    ● To determine a recommended dosage of pacritinib for further clinical studies
    ● Determinar una posología recomendada de pacritinib para futuros estudios clínicos.
    E.2.2Secondary objectives of the trial
    ● To examine the dose–response relationship for efficacy, as measured by spleen volume reduction (SVR) using MRI or CT and TSS using the Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score version 2.0 (MPN-SAF TSS 2.0)

    ● To examine the dose–response relationship for safety with a focus on AEs of interest

    ● To further characterize the pharmacokinetics (PK) and pharmacodynamics (PD) of pacritinib
    ● Examinar la relación entre la dosis y la respuesta en cuanto a la eficacia, determinada mediante la reducción del volumen esplénico (RVE) a través de resonancia magnética (RM) o tomografía axial computarizada (TAC) y la puntuación de los síntomas totales (PST) mediante el instrumento MPN-SAF TSS 2.0
    ● Examinar la relación entre la dosis y la respuesta en cuanto a la seguridad, centrando la atención en los acontecimientos adversos (AA) de interés
    ● Describir mejor la farmacocinética (FC) y la farmacodinámica (FD) de pacritinib
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1. PMF, PPV-MF, or PET-MF (as defined by Tefferi and Vardiman 2008)

    2. DIPSS Intermediate-1, Intermediate -2, or High risk (Passamonti et al 2010)

    3. Prior ruxolitinib treatment failure or intolerance as defined by:

    a. Treatment for ≥6 months with inadequate efficacy response (any measure) in the judgement of the investigator

    b. Treatment for ≥28 days complicated by either:

    i. RBC transfusion
    ii. NCI CTCAE grade ≥3 AEs of thrombocytopenia, anemia, hematoma, and/or hemorrhage while being treated with a dosage of <20 mg BID

    4. Palpable splenomegaly ≥5 cm below the lower costal margin (LCM) in the midclavicular line as assessed by physical examination

    5. Platelet count of ≤100,000/μL at any time during the screening period and prior to first dose of pacritinib, including patients who are platelet transfusion-dependent

    6. TSS of ≥10 on the MPN-SAF TSS 2.0

    7. Age ≥18 years old

    8. Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2

    9. Peripheral blast count of <10%

    10. Absolute neutrophil count of >500/μL

    11. Adequate liver and renal function, defined by liver transaminases (aspartate aminotransferase [AST]/serum glutamic oxaloacetic transaminase [SGOT] and alanine aminotransferase [ALT]/serum glutamic pyruvic transaminase [SGPT]), ≤3 × the upper limit of normal (ULN) (AST/ALT ≤5 × ULN if transaminase elevation is related to MF), direct bilirubin ≤4× ULN, and creatinine ≤2.5 mg/dL

    12. Adequate coagulation function, defined by prothrombin time (PT)/international normalized ratio (INR), partial thromboplastin time (PTT), or thrombin time (TT) of ≤1.5 × ULN

    13. Left ventricular cardiac ejection fraction of ≥45% by echocardiogram or multigated acquisition (MUGA) scan

    14. QTc interval of <450 ms as assessed by ECG and corrected by the Fredericia method

    15. If fertile, willing to use effective birth control methods during the study

    16. Willing to undergo and able to tolerate frequent MRI or CT assessments during the study

    17. Able to understand and willing to complete symptom assessments using a patient-reported outcomes instrument

    18. Provision of informed consent
    1. MFP, MF-PPV, o MF-PTI (según la definición de Tefferi y Vardiman 2008)

    2. Riesgo intermedio-1, intermedio-2 o alto según el DIPSS (Passamonti et al 2010)

    3. Fracaso de un tratamiento anterior con ruxolitinib o intolerancia a dicho tratamiento, según se define por:
    a. Tratamiento durante ≥ 6 meses con respuesta de la eficacia inadecuada (cualquier medida) a criterio del investigador
    b. Tratamiento durante ≥ 28 días complicado por
    i. Transfusión de eritrocitos
    ii. AA de grado ≥ 3 según los criterios CTCAE del Instituto nacional contra el cáncer de los EE. UU. (National Cancer Institute) (NCI) de trombocitopenia, anemia, hematoma, o hemorragia durante el tratamiento con una dosis < 20 mg 2 v/d.

    4. Esplenomegalia palpable ≥ 5 cm por debajo del reborde costal inferior en la línea media clavicular según la evaluación mediante exploración física

    5. Cifra de plaquetas ≤ 100 000/μl en cualquier momento durante el período de selección y antes de la primera dosis de pacritinib, incluidos los pacientes que dependen de transfusiones de plaquetas

    6. PST ≥ 10 en el MPN-SAF TSS 2.0

    7. Edad ≥ 18 años

    8. Estado funcional del Grupo Oncológico Cooperativo de la Costa Este (ECOG) de 0 a 2.

    9. Recuento de hemoblastos periféricos < 10 %

    10. Cifra absoluta de neutrófilos > 500/μl

    11. Función hepática y renal adecuada, definida por un nivel de transaminasas hepáticas (aspartato aminotransferasa [ASAT]/transaminasa glutámico-oxalacética en suero [SGOT] y alanina aminotransferasa [ALAT]/transaminasa glutámico-pirúvica en suero [SGPT]) ≤ 3 × límite superior de la normalidad (LSN) (ASAT/ALAT ≤ 5 × LSN si la elevación de las transaminasas está relacionada con la MF), bilirrubina directa ≤ 4× LSN y creatinina ≤ 2,5 mg/dl

    12. Función de coagulación adecuada, definida por un tiempo de protrombina (TP)/índice internacional normalizado (IIN), tiempo de tromboplastina parcial (TTP) o tiempo de trombina (TT) de ≤ 1,5 × LSN

    13. Fracción de eyección ventricular izquierda ≥ 45 % mediante ecocardiograma o ventriculografía isotópica (MUGA)

    14. Intervalo QTc de < 450 ms según la evaluación mediante ECG y corregido con el método de Fredericia

    15. Si el paciente es fértil, voluntad de utilizar métodos anticonceptivos eficaces durante el estudio

    16. Voluntad de someterse a evaluaciones mediante RM o TAC con frecuencia durante el estudio y ser capaz de tolerarlas

    17. Capacidad de entender y voluntad de completar las evaluaciones de síntomas mediante un instrumento de resultados percibidos por el paciente

    18. Concesión del consentimiento informado
    E.4Principal exclusion criteria
    1. Life expectancy <6 months

    2. Completed ASCT or are eligible for and willing to complete ASCT

    3. History of splenectomy or planning to undergo splenectomy

    4. Splenic irradiation within the last 6 months

    5. Previously treated with pacritinib

    6. Treatment with anticoagulation or antiplatelet agents, except for aspirin dosages of ≤100 mg per day, within the last 2 weeks

    7. Treatment with a potent cytochrome P450 (CYP450) inducer within the last 2 weeks

    8. Treatment with medications that can prolong the QTc interval within the last 2 weeks

    9. Significant recent bleeding history defined as NCI CTCAE grade ≥2 within the last 3 months, unless precipitated by an inciting event (e.g., surgery, trauma, injury)

    10. Any history of CTCAE grade ≥2 non-dysrhythmia cardiac conditions within the last 6 months. Patients with asymptomatic grade 2 non-dysrhythmia cardiac conditions may be considered for inclusion, with the approval of the medical monitor, if stable and unlikely to affect patient safety.

    11. New York Heart Association Class II, III, or IV congestive heart failure

    12. Any history of CTCAE grade ≥2 cardiac dysrhythmias within the last 6 months. Patients with non-QTc CTCAE grade 2 cardiac dysrhythmias may be considered for inclusion, with the approval of the medical monitor, if the dysrhythmias are stable, asymptomatic, and unlikely to affect patient safety.

    13. QTc prolongation >450 ms or other factors that increase the risk for QT interval prolongation (e.g., heart failure, hypokalemia [defined as serum potassium <3.0 mEq/L that is persistent and refractory to correction], family history of long QT interval syndrome, or concomitant use of medications that may prolong QT interval)

    14. Any gastrointestinal or metabolic condition that could interfere with absorption of oral medication

    15. Inflammatory or chronic functional bowel disorder such as Crohn’s Disease, inflammatory bowel disease, chronic diarrhea, or constipation

    16. Other malignancy within the last 3 years, other than curatively treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, organ-confined or treated nonmetastatic prostate cancer with negative prostate-specific antigen, in situ breast carcinoma after
    complete surgical resection, or superficial transitional cell bladder carcinoma

    17. Uncontrolled intercurrent illness, including, but not limited to, ongoing active infection or psychiatric illness or social situation that, in the judgment of the treating physician, would limit compliance with study requirements

    18. Known seropositivity for human immunodeficiency virus

    19. Known active hepatitis A, B, or C virus infection

    20. Women who are pregnant or lactating
    1. Esperanza de vida < 6 meses

    2. Alotrasplante de hemocitoblastos (ATHB) o ser elegible para someterse a un ATHB y estar dispuesto a ello

    3. Antecedentes de esplenectomía o que prevé someterse a una esplenectomía

    4. Irradiación esplénica en los últimos 6 meses

    5. Tratado anteriormente con pacritinib

    6. Tratamiento con anticoagulantes o antiagregantes plaquetarios, a excepción de ácido acetilsalicílico a dosis ≤ 100 mg al día, en las últimas 2 semanas

    7. Tratamiento con un inductor potente del citocromo P450 (CYP450) en las últimas 2 semanas

    8. Tratamiento con medicamentos que prolongan el intervalo QTc en las últimas 2 semanas

    9. Antecedentes de hemorragias recientes significativas, definidas como de grado ≥ 2 según los criterios CTCAE del NCI en los últimos 3 meses, a menos que se vean precipitadas por un acontecimiento causal (como cirugía, traumatismo o lesión)

    10. Antecedentes de afecciones cardíacas distintas de la arritmia de grado ≥ 2 según los CTCAE en los últimos 6 meses. Los pacientes con afecciones cardíacas asintomáticas distintas de la arritmia de grado 2 pueden ser considerados para su inclusión, con la aprobación del supervisor médico, si están estables y es improbable que afecten a la seguridad del paciente.

    11. Insuficiencia cardíaca congestiva de clase II, III o IV según la Asociación cardíaca de Nueva York (New York Heart Association)

    12. Antecedentes de arritmias cardíacas de grado >= 2 según los CTCAE en los últimos 6 meses. Los pacientes con arritmias cardíacas distintas de QTc de grado 2 según los CTCAE pueden ser considerados para su inclusión, con la aprobación del supervisor médico, si las arritmias están estables y asintomáticas y es improbable que afecten a la seguridad del paciente.

    13. La prolongación de QTc > 450 ms u otros factores que aumentan el riesgo de prolongación del intervalo QT (como insuficiencia cardíaca, hipopotasiemia [definida como potasio sérico <3,0 mEq/l que es persistente y resistente a la corrección], antecedentes familiares de síndrome del intervalo QT largo o uso concomitante de medicamentos que podrían prolongar el intervalo QT)

    14. Cualquier afección gastrointestinal o metabólica que pudiera interferir con la absorción del medicamento oral

    15. Trastorno de la función intestinal inflamatorio o crónico, como la enfermedad de Crohn, la enteropatía inflamatoria, la diarrea crónica o el estreñimiento

    16. Otra neoplasia maligna en los últimos 3 años, distinta del carcinoma basocelular o epidermoide cutáneo tratado con intención curativa, el carcinoma localizado de cuello de útero, el cáncer de próstata no metastásico tratado o confinado en un órgano con antígeno prostático negativo, el carcinoma de mama localizado después de resección quirúrgica completa o el carcinoma urotelial superficial

    17. Enfermedad intercurrente no controlada, incluidas, entre otras, infección activa o enfermedad psiquiátrica o situación social en curso que, a juicio del médico responsable del tratamiento, limitaría el cumplimiento de los requisitos del estudio

    18. Seropositividad conocida por el virus de la inmunodeficiencia humana

    19. Infección activa conocida por el virus de la hepatitis A, B o C

    20. Mujeres embarazadas o lactantes
    E.5 End points
    E.5.1Primary end point(s)
    The primary efficacy variable for dosage selection is the percent reduction in spleen volume from baseline.

    The primary safety measure for dosage selection is the percentage of patients with CTCAE grade ≥3 cardiac AEs (Standardized MedDRA Query [SMQ]), CTCAE grade ≥3 hemorrhage AEs (SMQ), CTCAE grade ≥4 thrombocytopenia toxicity (central laboratory based), or CTCAE grade ≥4 anemia toxicity (central laboratory based).
    La variable principal de la eficacia para la elección de la posología es la reducción porcentual en el volumen esplénico desde el inicio

    La medida principal de la seguridad para la elección de la posología es el porcentaje de pacientes con AA cardíacos de grado ≥ 3 según los CTCAE (Consulta normalizada de MedDRA [SMQ]), AA hemorrágicos de grado ≥ 3 según los CTCAE (SMQ), toxicidad de trombocitopenia de grado ≥ 4 según los CTCAE (basada en la evaluación del laboratorio central) o toxicidad de anemia de grado ≥ 4 según los CTCAE (basada en la evaluación del laboratorio central).
    E.5.1.1Timepoint(s) of evaluation of this end point
    The primary endpoint is measured at Weeks 12 and 24.
    La variable principal se medirá en la semana 12 y 24.
    E.5.2Secondary end point(s)
    Other supportive measures for evaluation as part of the dose–response relationship include: the percentage of patients who achieve at least 35% reduction in spleen volume; % TSS reduction from baseline; and the percentage of patients with at least 50% reduction in TSS.

    All other safety data including AEs, death, and clinical laboratory measures will be used as supportive measures for evaluation of pacritinib dose-safety relationship.
    Otras medidas de apoyo para la evaluación como parte de la relación entre la dosis y la respuesta son: el porcentaje de pacientes que logran una reducción de, al menos, el 35 % en el volumen esplénico; la disminución porcentual en la PST con respecto al inicio y el porcentaje de pacientes con una reducción de, al menos, el 50 % en la PST.

    El resto de datos de la seguridad, incluidos los AA, los fallecimientos y las medidas del laboratorio clínico se usarán como medidas de apoyo para evaluar la relación entre la dosis de pacritinib y la seguridad.
    E.5.2.1Timepoint(s) of evaluation of this end point
    The secondary endpoint is measured at Weeks 12 and 24.
    La variable secundaria se medirá en la semana 12 y 24.
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response Yes
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled No
    E.8.1.1Randomised Yes
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial3
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned3
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA21
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    France
    Germany
    Hungary
    Italy
    Spain
    Sweden
    United Kingdom
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    UVUP
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years1
    E.8.9.1In the Member State concerned months4
    E.8.9.1In the Member State concerned days29
    E.8.9.2In all countries concerned by the trial years1
    E.8.9.2In all countries concerned by the trial months9
    E.8.9.2In all countries concerned by the trial days15
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 50
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 55
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state10
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 40
    F.4.2.2In the whole clinical trial 105
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    The sponsor intends to allow patients to continue to receive pacritinib after completing the study if the patient and investigator feel they are benefitting from pacritinib treatment and if allowed by the governing regulatory agency.
    El promotor tiene la intención de permitir que los pacientes continúen recibiendo pacritinib después de completar el estudio si el paciente y el investigador creen que se está beneficiando del tratamiento con pacritinib y si esta permitido por la agencia reguladora gubernamental.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2017-09-11
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2017-09-01
    P. End of Trial
    P.End of Trial StatusOngoing
    The status of studies in GB is no longer updated from 1.1.2021
    For the UK, as from 1.1.2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-2021 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    Legal notice
    EMA HMA